Progress and perspectives of post-operative adjuvant chemotherapy for adenocarcinoma of the pancreas

DOI Web Site 37 References Open Access
  • NAKAMORI Shoji
    Department of Hepato-Biliary-Pancreatic Surgery, Osaka National Hospital
  • MAEDA Sakae
    Department of Hepato-Biliary-Pancreatic Surgery, Osaka National Hospital
  • HAMA Naohiro
    Department of Hepato-Biliary-Pancreatic Surgery, Osaka National Hospital
  • MIYAMOTO Atsushi
    Department of Hepato-Biliary-Pancreatic Surgery, Osaka National Hospital

Bibliographic Information

Other Title
  • 膵癌術後化学療法の進歩と展望

Search this article

Description

Adenocarcinoma of the pancreas carries a poor prognosis after curative resection, which offers the only chance for a cure. To improve such poor outcomes, several trials for post-operative adjuvant therapies have been carried out. Under the present situation in which the mainstay of treatment following resection is based primarily on gemcitabine, promising new therapeutic agents, and prognostic, as well as predictive biomarkers, are being reported. In this article, the history of post-operative therapies is reviewed and the future directions are discussed.

Journal

  • Suizo

    Suizo 29 (6), 878-884, 2014

    Japan Pancreas Society

References(37)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top